Mirjam Korporal‐Kuhnke

Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks

Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD

Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)

Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity—a potential diagnostic pitfall in patients with MOG-EM/MOGAD

Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision

Time to Disability Milestones and Annualized Relapse Rates in <scp>NMOSD</scp> and <scp>MOGAD</scp>

Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017)

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease

Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Peripheral nerve involvement in multiple sclerosis: Demonstration by magnetic resonance neurography

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome